Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-14
DOI
10.1038/s41598-020-74195-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LRRK2 in Parkinson disease: challenges of clinical trials
- (2020) Eduardo Tolosa et al. Nature Reviews Neurology
- LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
- (2019) Farzaneh Atashrazm et al. MOVEMENT DISORDERS
- Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
- (2019) Ye Zhao et al. DRUGS
- Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients
- (2019) Belén Fernández et al. BIOCHEMICAL JOURNAL
- LRRK2 activation in idiopathic Parkinson’s disease
- (2018) Roberto Di Maio et al. Science Translational Medicine
- Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
- (2017) Andrew B. West EXPERIMENTAL NEUROLOGY
- LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease
- (2017) Evan H Howlett et al. HUMAN MOLECULAR GENETICS
- GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
- (2017) Marian Blanca Ramírez et al. HUMAN MOLECULAR GENETICS
- Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells
- (2017) Kenneth Thirstrup et al. Scientific Reports
- Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease
- (2016) Kyle B. Fraser et al. MOVEMENT DISORDERS
- Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019SLRRK2carriers
- (2016) Kyle B. Fraser et al. NEUROLOGY
- Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
- (2016) G. Perera et al. Scientific Reports
- Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
- (2016) Martin Steger et al. eLife
- Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
- (2016) E. Lobbestael et al. Scientific Reports
- Centrosomes are multifunctional regulators of genome stability
- (2015) Dorothy A. Lerit et al. CHROMOSOME RESEARCH
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)
- (2014) Raghava R Kethiri et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Ten Years and Counting: Moving Leucine-Rich RepeatKinase 2 Inhibitors to the Clinic
- (2014) Andrew B. West MOVEMENT DISORDERS
- Mitochondrial DNA damage: Molecular marker of vulnerable nigral neurons in Parkinson's disease
- (2014) Laurie H. Sanders et al. NEUROBIOLOGY OF DISEASE
- Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications
- (2014) Iakov N. Rudenko et al. Neurotherapeutics
- Lack of Correlation between the Kinase Activity of LRRK2 Harboring Kinase-Modifying Mutations and Its Phosphorylation at Ser910, 935, and Ser955
- (2014) Genta Ito et al. PLoS One
- Mitochondrial DNA Damage as a Peripheral Biomarker for Mitochondrial Toxin Exposure in Rats
- (2014) Laurie H. Sanders et al. TOXICOLOGICAL SCIENCES
- In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2
- (2014) Renée Vancraenenbroeck et al. Frontiers in Molecular Neuroscience
- LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status
- (2014) April Reynolds et al. Frontiers in Molecular Neuroscience
- Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle
- (2013) Evy Lobbestael et al. BIOCHEMICAL JOURNAL
- LRRK2 secretion in exosomes is regulated by 14-3-3
- (2013) K. B. Fraser et al. HUMAN MOLECULAR GENETICS
- LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction
- (2013) Laurie H. Sanders et al. NEUROBIOLOGY OF DISEASE
- Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)
- (2012) Xianming Deng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity
- (2012) C. Yao et al. HUMAN MOLECULAR GENETICS
- Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
- (2012) Z. Sheng et al. Science Translational Medicine
- Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson’s disease mutations and LRRK2 pharmacological inhibition
- (2011) Elizabeth A. Doggett et al. JOURNAL OF NEUROCHEMISTRY
- Mitochondrial degradation by autophagy (mitophagy) in GFP-LC3 transgenic hepatocytes during nutrient deprivation
- (2010) Insil Kim et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization
- (2010) Nicolas Dzamko et al. BIOCHEMICAL JOURNAL
- 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
- (2010) R. Jeremy Nichols et al. BIOCHEMICAL JOURNAL
- Genome-wide association study reveals genetic risk underlying Parkinson's disease
- (2009) Javier Simón-Sánchez et al. NATURE GENETICS
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
- (2008) Daniel G Healy et al. LANCET NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now